Our leadership includes noted experts from academia and industry who share a singular goal: to re-imagine skin science and deliver important new treatments to the millions of patients living with chronic skin conditions.
Andrew joined Dermira in April 2020 and has more than 30 years’ experience in the pharmaceutical and biotech industry.
Prior to joining Dermira, Andrew served as the Chief Commercial Officer and Interim CEO of Immunocore, a privately held UK Biotech company.
He has served in a number of global leadership positions at Eli Lilly and Company across multiple therapeutic areas and geographies including as VP International Business Unit Leader Oncology, President Biomedicines Business Unit, Australia, Canada and Europe and SVP Digital Ventures.
Andrew has served on a number of industry trade associations including Chairman of the European Markets Committee at EFPIA and a Board member of the BioIndustry Association in the UK.
Andrew has a degree in Biochemistry from the University of Cardiff.
Virginia joined Dermira in 2016 and currently serves as Chief Business Officer, SVP. Prior to the Lilly acquisition, Virginia served as VP of Corporate Development and Strategy for Dermira and led strategic partnering efforts and Dermira’s Alliance function.
Prior to joining Dermira, Virginia held various senior corporate and business development roles in Biotech companies including DSM Biomedical, Intrexon Corporation, and FibroGen Inc., leading and executing numerous transactions across therapeutic areas including medical devices. In addition, Virginia has extensive corporate development and transaction experience both in the start-up environment (Cellastra Inc., EPL Technologies) and as a third-party consultant advising on business development initiatives.
Virginia holds an MBA from St. Joseph’s University and a BA from Temple University.
Bill joined Dermira in 2016 and currently serves as Chief Scientific Affairs Officer. Prior to joining Dermira, Bill was Vice President for Medical Affairs at Neurocrine Biosciences and has held senior scientific and medical affairs roles with Merck Research Laboratories, where he served as Vice President, Global Center for Scientific Affairs, and Amgen, where he served as Vice President, Global Scientific Affairs. Bill also held positions of increasing responsibility with Novartis in the Global Business Development and Licensing group and with Bristol-Myers Squibb in the Medical Affairs group.
Bill earned his Pharm.D. from the University of Texas Health Science Center, San Antonio, and his B.S. in pharmacy from the University of Texas, Austin.
Harp Dhaliwal joined Dermira in 2018 and currently serves as Senior Vice President, Supply Chain, Manufacturing and Procurement. Harp has 24 years of experience in engineering, operations strategy, manufacturing, and supply chain. Prior to Dermira, Harp was in a similar role with an Oncology focused company, Medivation, until its acquisition by Pfizer. Harp stayed on with Pfizer to lead the operations integration. Previously, Harp had a long career at Biogen, where he started as the Director of clinical supply chain and progressed to roles with increasing levels of responsibility including the role of Chief Procurement Officer where he was responsible for managing $3 Billion of enterprise-wide spend. Harp also has experience managing medical device operations with Boston Scientific. He spent the formative years of his career as an engineer with Fluor, as an entrepreneur with Paradigm Environmental, and as a management consultant with PRTM.
Harp holds a BASc in Chemical Engineering from the University of British Columbia and an MBA from Queen’s University in Canada.
Delphine currently serves as Senior Vice President, Pharmaceutical Sciences and oversees all technical development activities for the QBREXZA® (glycopyrronium) cloth franchise. Delphine joined Dermira in 2011 to establish Dermira’s fully virtual CMC, manufacturing, and supply chain capabilities enabling the successful development, approval, and launch of Qbrexza . Delphine has over 22 years of product development experience spanning all stages of development, small molecules and biologics. Prior to joining Dermira, Delphine served as Vice President, Pharmaceutical R&D at Anacor Pharmaceuticals, and held various leadership roles at ALZA Corporation (a Johnson & Johnson) and Cellegy Pharmaceuticals. Delphine conducted her postdoctoral training at the University of California, San Francisco, holds of Ph.D. in Pharmaceutical Sciences from the University of Cincinnati, and a Master’s degree in Chemical Engineering and Chemistry from Chimie ParisTech, Paris, France.
Gary Thompson joined Dermira in 2018 and currently serves as V.P., Compliance Officer managing all aspects of Dermira’s Compliance Program. Prior to Dermira, Gary served for 5 years as V.P. Compliance Officer for NuVasive, Inc., where he led all aspects of NuVasive’s global business ethics and compliance program addressing, among other things, primary U.S. health care compliance and international anti-corruption risks, and served as Privacy Officer managing HIPAA and international privacy compliance.
Gary previously served as Senior Counsel with Akin Gump Strauss Hauer & Feld, LLP in Washington, DC. Gary’s practice focused on health care fraud and abuse law and corporate compliance. He represented health industry clients in False Claims Act (“FCA”) and qui tam investigations, involving health care fraud and abuse laws. He counseled health industry clients, including medical device companies, on compliance with fraud and abuse laws. He negotiated Corporate Integrity Agreements (“CIAs”) and counseled clients on adherence to CIAs. He conducted internal investigations, including those under the direction of Board Audit or Compliance Committees, and evaluated the necessity of making voluntary disclosures to regulatory and/or enforcement bodies. Gary led Akin Gump’s Compliance Program Advisory Services, where he provided extensive counseling to health industry clients on the development, implementation, and maintenance of corporate compliance programs and performed effectiveness reviews of compliance programs.
Additional prior experience includes serving as Senior Counsel within the Office of Inspector General, Washington, D.C., where he represented the OIG’s interest in health care fraud investigations and cases, and assisted the Department of Justice in developing factual and legal bases and litigation strategies for enforcement actions and reviewed global settlement agreements. Gary also served as Senior Vice President for Corporate Governance and Regulatory Affairs at the Council of Ethical Organizations, a nonprofit, non-partisan organization dedicated to promoting corporate ethics and compliance, primarily within the healthcare industry.
Gary earned his J.D. degree from Washington & Lee University School of Law, and a Bachelor of Arts, cum laude, from Claremont McKenna College. He has authored best practice and groundbreaking articles on corporate ethics and compliance issues, and health care fraud and abuse. Gary has been invited to deliver numerous speeches and presentations on corporate compliance and other health care fraud and abuse compliance issues.
Tracy VanDenBerg currently serves as Vice President, Head of Human Resources. Tracy joined Dermira in 2019 and previously led Total Rewards for the company in addition to her role as Senior Director, Human Resources Business Partner to the Product Development and Technical Operations organizations. Prior to Dermira, Tracy led Human Resources, Finance and Administration for Tencent America, LLC and has served in various Human Resources roles at TiVo, Boston Scientific, America Online and Arthur Andersen, LLP. Tracy earned an MBA from San Jose State University and Bachelor’s degrees in both Political Science and International Relations from the University of Southern California.
